Universe Pharmaceuticals (UPC)
NASDAQ:UPC
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.72M
Enterprise Value-$22.57M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-13.09
Enterprise Value/Revenue-1.26
Enterprise Value/Gross Profit-3.58
Enterprise Value/Ebitda7.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow absolute debt and a ~0.16 debt-to-equity in 2025 provide durable financial flexibility. This conservative capital structure reduces refinancing pressure, supports investment optionality, and lengthens runway while revenues recover, making balance-sheet risk lower over the next several quarters.
Margin Recovery TrendA rebound in gross margin to ~35% and an improving net margin trajectory indicate that product mix, pricing or cost controls are beginning to work. If sustained, higher gross margins can materially improve operating leverage and reduce cash burn as volumes stabilize.
Nationwide Distribution FootprintA broad China distribution network and diversified product lines (TCM derivatives, biomedical drugs, instruments, supplements) provide structural market access and multiple revenue channels. This enduring commercial reach supports recovery potential and limits single-product concentration risk.
Bears Say
Multi-year Revenue DeclineA sustained drop from ~$48M to ~$17.9M over four years signals persistent demand, market share, or product issues. Long-term revenue contraction undermines scale economies, weakens bargaining power, and makes margin recovery and fixed-cost absorption more difficult over the coming quarters.
Consistent Negative Cash GenerationPersistent negative operating and free cash flow shows the business currently consumes cash to operate. Dependence on external funding or equity dilution is likely if losses persist, restricting the company's ability to self-fund R&D, commercial expansion, or buffer against shocks in the medium term.
Ongoing Losses And Negative ROEMulti-year net losses and negative ROE erode shareholders' capital and signal structural profitability problems. Continued negative returns increase the risk of equity dilution, constrain strategic investment, and challenge management to restore sustainable profitability within several quarters.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.72M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 563,338 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―